Related Experiment Video
Updated: Aug 14, 2025
Author Spotlight: Advancing Treatment Approaches with Adipose-Derived Stem Cells
Published on: January 12, 2024
Mesenchymal Stem Cells Therapy for COVID-19: From Basic Research to Clinical Trial
Ya-Chao Tao1,2, En-Qiang Chen1,2
1Center of Infectious Diseases, West China Hospital, Sichuan University, Chengdu, Sichuan-610041, P.R. China.
Abstract:
The novel pathogenic severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes coronavirus disease 2019 (COVID-19), a serious challenge for human health. In severe cases, patients suffer from acute respiratory distress syndrome even organ failure, usually owing to the dysregulated immune response and widespread inflammation. Considering that there is no known cure for COVID-19 despite the increased morbidity and mortality rate of COVID-19, modalities targeting immunity and inflammation may be promising therapeutics against COVID-19. Mesenchymal stem cells (MSCs) possessing immunomodulatory, anti-inflammatory, anti-apoptotic, and antiviral properties, can be of potential benefit to a subset of severe and critically ill patients with COVID-19. In the present study, we described the underlying mechanisms of MSCs therapy and provided a thorough research study on the recent clinical trials of MSCs for SARS-CoV-2 infection.
Insights
Mesenchymal stem cells (MSCs) show promise for treating severe COVID-19 by modulating the immune response and reducing inflammation. Research explores MSC mechanisms and clinical trials for SARS-CoV-2 infection.
Area of Science:
- Immunology
- Regenerative Medicine
- Virology
Background:
- Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes COVID-19, leading to severe respiratory distress and organ failure due to uncontrolled inflammation.
- Current COVID-19 treatments lack definitive cures, highlighting the need for novel therapeutic strategies targeting immune dysregulation.
Purpose of the Study:
- To elucidate the therapeutic mechanisms of mesenchymal stem cells (MSCs) in combating SARS-CoV-2 infection.
- To review and analyze recent clinical trials investigating MSCs as a treatment for severe and critical COVID-19.
Main Methods:
- Review of scientific literature on MSC immunomodulatory, anti-inflammatory, anti-apoptotic, and antiviral properties.
- Analysis of clinical trial data assessing MSC efficacy and safety in COVID-19 patients.
Main Results:
- MSCs exhibit multifaceted therapeutic potential through immune modulation and inflammation reduction.
- Clinical trials indicate MSCs may benefit severe COVID-19 cases, though further research is ongoing.
Conclusions:
- Mesenchymal stem cells represent a promising therapeutic avenue for severe COVID-19 by mitigating hyperinflammation and organ damage.
- Continued investigation into MSC-based therapies is crucial for optimizing treatment strategies against SARS-CoV-2.
More Related Videos
07:03Isolation, Characterization, and Therapeutic Application of Extracellular Vesicles from Cultured Human Mesenchymal Stem Cells
Published on: September 23, 2022
07:45Ultrasound-guided Intracardiac Injection of Human Mesenchymal Stem Cells to Increase Homing to the Intestine for Use in Murine Models of Experimental Inflammatory Bowel Diseases
Published on: September 1, 2017
Related Concept Videos
01:19Mesenchymal Stem Cells
01:21Stem Cell Therapy for Tissue Regeneration
Types of Stem Cells used in Stem Cell Therapy
The two main cell...
01:17Stem Cell Culture